Cultivated meat

01Overview and value chain

Markers: [EC: NACE 10.11 (Processing & preserving of meat) | OECD: Food systems | Regulator: FDA (USA), EFSA (EU), MARA (CN)]

Cultivated meat — also called cell-cultured or lab-grown meat — is genuine animal muscle and fat tissue grown from a small biopsy of starter cells inside bioreactors, bypassing the need to raise and slaughter livestock. By decoupling meat from the animal, the route can cut the greenhouse-gas footprint of beef by up to 90 percent and uses roughly 95 percent less land and 80 percent less water than conventional husbandry, while reaching protein densities of 20–25 grams per 100 g comparable to a lean steak. Since Singapore approved the world’s first cultivated-chicken sale in December 2020, 11 companies across Singapore, the United States, Israel, Australia and the United Kingdom have secured regulatory clearance, and the front-runner production cost has fallen from a €250,000 proof-of-concept burger in 2013 to a restaurant-price patty today — a 99.999 percent reduction. Production economics now pivot on culture-media cost and bioreactor scale, with viable unit economics projected at 10,000–50,000-litre stirred-tank capacity.

The key directions of cultivated meat are:

1. Cell-line development & immortalization: isolating and engineering muscle and fat progenitor cells that divide indefinitely without animal serum, the biological foundation of every scaled process.
2. Animal-free culture media: replacing fetal bovine serum with plant- or microbe-derived amino-acid, growth-factor and vitamin formulations — the single largest cost driver, now reduced up to 80-fold by front-runners such as Mosa Meat.
3. Bioreactor scale-up (perfusion / stirred-tank): expanding cells from the flask to 2,000–250,000-litre vessels using perfusion and tangential-flow filtration for continuous harvest.
4. Scaffold & tissue structuring: seeding cells onto edible or removable fibre scaffolds and maturing them into whole-cut, layered or structured textures that ground mince cannot reach.

Sectoral value chain

[Biopsy & cell banking] ──> [Media formulation] ──> [Cell expansion] ──> [Differentiation]
                                                          │
                                                  (Scaffold seeding)
                                                          │
                                                          ▼
[Food service & retail] <─── [Structuring & harvest] <─────┘

Value chain levels

Cross-cutting technologies of the sector:

• Animal cell culture: aseptic propagation of vertebrate muscle, fat and stem cells in controlled bioreactors outside the living animal.
• Perfusion bioreactors: continuous stirred-tank and hollow-fibre systems that refresh media and harvest biomass, enabling high cell densities at scale.
• Tissue scaffolding: edible or removable fibre, hydrogel and 3D-printed matrices that organise cells into structured, meat-like architecture.

02US

The United States is the regulated commercial beachhead of cultivated meat, where a joint FDA–USDA framework has already cleared multiple companies and the largest production plants are now commissioned.

Cultivated chicken clearance, joint FDA–USDA pathway, large-scale plants

• Upside Foods: a Californian pioneer that holds FDA and USDA clearance for a whole-textured cultivated-chicken fillet and runs 2,000-litre production batches at its EPIC engineering centre, funded by a $400M Series C round in 2022.
• Good Meat: the cultivated-meat division of Eat Just that secured FDA safety clearance in March 2023 and the first USDA label approval in June 2023, and cut its production cost by 90 percent between 2018 and 2022 while deploying 250,000-litre bioreactor designs.
• Industry scale-up: Israel-founded, US-regulated Believer Meats became the fifth firm to receive an FDA “no questions” letter in July 2025 and commissioned a 12,000-tonne-per-year North Carolina plant, signalling the shift from restaurant tastings to industrial capacity.

03CN

China’s cultivated-meat programme is anchored by national-university research and tied to long-term protein-self-sufficiency and food-security goals, with a clear pathway from bench to pilot-scale production.

University spinouts, 2,000-litre pilot trials, national food-security mandate

• Zhouzi Future Food: the Nanjing Agricultural University incubated enterprise that produced China’s first cell-cultured meat in 2019 and, in 2025, built the country’s largest pilot plant — completing the world’s first 2,000-litre bioreactor scaled trial of cultivated pork at a 50-tonne-per-year capacity.
• National research base: Nanjing Agricultural University’s national key laboratory has run the underlying programme since 2009 and hosted the 2026 Global Forum on Cultured Meat, framing cultivated meat as a strategic “new productive force” for meat-protein supply.
• Policy tailwind: protein self-sufficiency and food-security targets underpin state support, with the Ministry of Agriculture and Rural Affairs (MARA) defining the regulatory pathway for novel animal-cell food products.

04EU

Europe pairs the field’s origin science with the most rigorous approval pathway, where a wave of cost-down engineering and the first EFSA novel-food filings are now converging.

EFSA novel-food pathway, cost-down engineering, Maastricht campus

• Mosa Meat: the Maastricht company whose co-founder Mark Post unveiled the first cultivated-beef burger in 2013, has cut its production cost by 99.999 percent and in January 2025 filed the EU’s first cultivated-beef (cultivated-fat) novel-food application; a €15M round in December 2025 lifted total funding past $156M and extended its runway to 2028.
• Meatable: the Delft-based developer whose opti-ox stem-cell technology — recognised by TIME as a best invention of 2024 — compresses the cell-cultivation cycle to four days and reached 500-litre pilot bioreactors, targeting profitable unit economics at 10,000-litre scale.
• Ivy Farm Technologies: a 2019 University of Oxford spinout producing cultivated beef on a three-tonne-per-year pilot bioreactor and partnering with Finland’s Synbio Powerlabs to scale toward 10,000-litre and 27,000-litre fermenters for first commercial sales.

05Leading companies and research institutes

06Tech stack and innovations

Cultivated meat converges vertebrate cell biology, bioreactor engineering and tissue structuring to reproduce the texture, flavour and nutrition of conventional meat without the animal.

1. Cell-line & media engineering:
   • Immortalised muscle and adipose progenitor lines are selected or gene-edited to divide indefinitely, removing the need for repeated animal biopsies and fetal bovine serum.
   • Serum-free media remain the dominant cost; Mosa Meat has cut growth-medium cost 80-fold since 2020 and fat-medium cost 66-fold, dragging the burger from a €250,000 proof of concept toward restaurant-price parity.
2. Perfusion & large-scale bioreactors:
   • Continuous perfusion with tangential-flow filtration sustains high cell densities and enables daily harvest, with Good Meat deploying 250,000-litre vessels and viable unit economics projected at 10,000–50,000-litre scale.
   • Scale-up rather than bespoke biology is now the binding constraint, which is why players partner with established bioreactor builders (ABEC, GEA, Esco Aster) rather than building capacity alone.
3. Scaffolding & structured whole cuts:
   • Edible fibre, hydrogel and 3D-printed matrices organise differentiated cells into layered, whole-muscle architecture, closing the gap between mince and the steaks, cutlets and fillets that extruded plant protein cannot reach.

07Value chains and production pipelines

Industrial pipeline of cultivated-meat manufacturing (HACCP / ISO 22000 food-safety standards)

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Biopsy & cell banking  │ ───> │ 2. Media formulation      │
└───────────────────────────┘      └───────────────────────────┘
                                                  │
                                                  ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Differentiation        │ <─── │ 3. Cell expansion         │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Structuring & harvest  │ ───> │ 6. Formulation & sales    │
└───────────────────────────┘      └───────────────────────────┘

Stage 1: Biopsy & cell banking

A small tissue sample is taken from a living or slaughtered food animal, and muscle and fat progenitor cells are isolated, characterised and banked as a master cell line that supplies all downstream production without further animals.

Stage 2: Media formulation

A serum-free nutrient broth of amino acids, sugars, salts, vitamins and growth factors is compounded from plant or microbial sources, replacing fetal bovine serum and setting both the cost and the sustainability profile of the final meat.

Stage 3: Cell expansion

Seed cells are grown in stirred-tank or perfusion bioreactors scaled from a few litres to 2,000–250,000 litres, with continuous media refresh and tangential-flow filtration sustaining high cell densities for daily biomass harvest.

Stage 4: Differentiation

Progenitor cells are switched to maturation media that drives them to become contractile muscle fibres and lipid-rich adipose tissue, reproducing the two cell populations that define the taste, texture and nutrition of meat.

Stage 5: Structuring & harvest

Differentiated cells are seeded onto edible fibre or hydrogel scaffolds, or extruded into aligned fibres, and matured into structured whole cuts that are then harvested and checked against food-safety specifications.

Stage 6: Formulation & sales

Structured tissue is blended with plant proteins, fats and seasonings into finished products — burgers, sausages, nuggets or whole cuts — then packaged, labelled under the applicable FDA, EFSA or MARA pathway, and distributed to restaurants and retail.